Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes

Heart and Vessels

Volumn 32, Issue 5, 2017, Pages 549-557

  Darabi, Faramarz ^a,b   Aghaei, Mahmoud ^a   Movahedian, Ahmad ^a   Elahifar, Armin ^b   Pourmoghadas, Ali ^b   Sarrafzadegan, Nizal ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute coronary syndrome; Adipocytokines; miR 21; Visfatin

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA 21; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; BIOLOGICAL MARKER; MICRORNA; MIRN21 MICRORNA, HUMAN;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ANALYZER; ARTICLE; ATHEROSCLEROSIS; AUTOMATION; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; BIOSYNTHESIS; BLOOD; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED;

ACUTE CORONARY SYNDROME; BIOMARKERS; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; MICRORNAS; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84992401684     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-016-0913-z     Document Type: Article

References (55)

1. Sarrafzadegan N, Gotay C (2015) CVD prevention in 2014: Advances in the prevention of cardiovascular disease. Nat Rev Cardiol 12:71–73
2. Anwaruddin S, Askari AT, Topol EJ (2007) Redefining risk in acute coronary syndromes using molecular medicine. J Am Coll Cardiol 49:279–289
3. Alfieri O, Mayosi BM, Park S-J, Sarrafzadegan N, Virmani R (2014) Exploring unknowns in cardiology. Nat Rev Cardiol 11:664–670
4. Armstrong EJ, Morrow DA, Sabatine MS (2006) Inflammatory biomarkers in acute coronary syndromes part I: introduction and cytokines. Circulation 113:e72–e75
5. Varnava AM, Mills PG, Davies MJ (2002) Relationship between coronary artery remodeling and plaque vulnerability. Circulation 105:939–943
6. Sakamoto N, Hoshino Y, Misaka T, Mizukami H, Suzuki S, Sugimoto K, Yamaki T, Kunii H, Nakazato K, Suzuki H, Saitoh SI (2014) Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome. Heart Vessels 29:165–170
7. W van Lammeren G, L Moll F, Jan De Borst G, PV de Kleijn D, PM de Vries JP, Pasterkamp G (2011) Atherosclerotic plaque biomarkers: beyond the horizon of the vulnerable plaque. Curr Cardiol Rev 7:22–27
8. Hellings WE, Peeters W, Moll FL, Pasterkamp G (2007) From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc Med 17:162–171
9. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
10. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:515–524
11. Small EM, Olson EN (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature 469:336–342
12. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C (2007) MicroRNAs in the human heart a clue to fetal gene reprogramming in heart failure. Circulation 116:258–267
13. Kumarswamy R, Volkmann I, Thum T (2011) Regulation and function of miRNA-21 in health and disease. RNA Biol 8:706–713
14. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C (2007) MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 100:1579–1588
15. Suárez Y, Fernández-Hernando C, Pober JS, Sessa WC (2007) Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100:1164–1173
16. Kim YJ, Hwang SJ, Bae YC, Jung JS (2009) MiR-21 regulates adipogenic differentiation through the modulation of TGF-β signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells 27:3093–3102
17. Cheng KH, Chu CS, Lee KT, Lin TH, Hsieh CC, Chiu CC, Voon WC, Sheu SH, Lai WT (2008) Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) 32:268–274
18. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–430
19. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748–1758
20. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC (2004) Pre–B cell colony–enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113:1318–1327
21. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B (2007) Increased expression of Visfatin in macrophages of human unstable carotid and coronary atherosclerosis possible role in inflammation and plaque destabilization. Circulation 115:972–980
22. Dattaroy D, Pourhoseini S, Das S, Alhasson F, Seth RK, Nagarkatti M, Michelotti GA, Diehl AM, Chatterjee S (2015) Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 308:G298–G312
23. Estep JM, Goodman Z, Sharma H, Younossi E, Elarainy H, Baranova A, Younossi Z (2015) Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. Liver Int 35:1367–1372
24. Estep JM, Goodman Z, Sharma H, Younossi E, Elarainy H, Baranova A, Younossi Z (2015) Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. Liver Int 35:1367–1372
25. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147
26. American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1):S67–S74
27. Wintersperger BJ, Nikolaou K (2005) Basics of cardiac MDCT: techniques and contrast application. Eur Radiol 15:B2–B9
28. Desjardins P, Conklin D (2010) NanoDrop microvolume quantitation of nucleic acids. J Vis Exp 45
29. Becker C, Hammerle-Fickinger A, Riedmaier I, Pfaffl MW (2010) mRNA and microRNA quality control for RT-qPCR analysis. Methods 50:237–243
30. −ΔΔCT method. Methods 25:402–408
31. Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50:298–301
32. Anzai A, Maekawa Y, Kodaira M, Mogi S, Arai T, Kawakami T, Kanazawa H, Hayashida K, Yuasa S, Kawamura A, Fukuda K (2015) Prognostic implications of optimal medical therapy in patients undergoing percutaneous coronary intervention for acute coronary syndrome in octogenarians. Heart Vessels 30:186–192
33. Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32:2045–2051
34. Hosin AA, Prasad A, Viiri LE, Davies AH, Shalhoub J (2014) MicroRNAs in atherosclerosis. J Vasc Res 51:338–349
35. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006
36. Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S (2011) Serum levels of vaspin and Visfatin in patients with coronary artery disease—Kozani study. Clin Chim Acta 412:48–52
37. Santovito D, Mezzetti A, Cipollone F (2012) MicroRNAs and atherosclerosis: new actors for an old movie. Nutr Metab Cardiovasc Dis 22:937–943
38. Small EM, Frost RJ, Olson EN (2010) MicroRNAs add a new dimension to cardiovascular disease. Circulation 121:1022–1032
39. Elzenaar I, Pinto YM, Oort R (2013) MicroRNAs in heart failure: new targets in disease management. Clin Pharmacol Ther 94:480–489
40. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666
41. Selcuklu SD, Donoghue MT, Spillane C (2009) miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 37:918–925
42. Zhang C (2008) MicroRNomics: a newly emerging approach for disease biology. Physiol Genomics 33:139–147
43. Raitoharju E, Oksala N, Lehtimäki T (2013) MicroRNAs in the atherosclerotic plaque. Clin Chem 59:1708–1721
44. Tsai P-C, Liao Y-C, Wang Y-S, Lin H-F, Lin R-T, Juo S-H (2013) Serum microRNA-21 and microRNA-221 as potential biomarkers for cerebrovascular disease. J Vasc Res 50(4):346–354
45. Fan X, Wang E, Wang X, Cong X, Chen X (2014) MicroRNA-21 is a unique signature associated with coronary plaque instability in humans by regulating matrix metalloproteinase-9 via reversion-inducing cysteine-rich protein with Kazal motifs. Exp Mol Pathol 96:242–249
46. Sethi JK, Vidal-Puig A (2005) Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 11:344–347
47. Adya R, Tan BK, Punn A, Chen J, Randeva HS (2008) Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3 K/Akt signaling pathways: novel insights into Visfatin-induced angiogenesis. Cardiovasc Res 78:356–365
48. Van der Wal AC, Becker AE (1999) Atherosclerotic plaque rupture–pathologic basis of plaque stability and instability. Cardiovasc Res 41:334–344
49. Olivares R, Ducimetière P, Claude JR (1993) Monocyte count: a risk factor for coronary heart disease? Am J Epidemiol 137:49–53
50. Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94:1543–1553
51. Liu SW, Qiao SB, Yuan JS, Liu DQ (2009) Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 71:202–207
52. Assmann G, Schulte H, von Eckardstein A, Huang Y (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124:S11–S20
53. Keller P, Gburcik V, Petrovic N, Gallagher IJ, Nedergaard J, Cannon B, Timmons JA (2011) Gene-chip studies of adipogenesis regulated microRNAs in mouse primary adipocytes and human obesity. BMC Endocr Disord 11:7
54. Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, Fukami T, Yokoi T (2011) PPARα is regulated by miR-21 and miR-27b in human liver. Pharm Res 28:2467–2476
55. Yang CC, Deng SJ, Hsu CC, Liu BH, Lin EC, Cheng WT, Wang PH, Ding ST (2010) Visfatin regulates genes related to lipid metabolism in porcine adipocytes. J Anim Sci 88:3233–3241